Market›Health Care›Pharmaceuticals›Pharmaceuticals
AN2 THERAPEUTICS INC

ANTX

$4.34Mar 25, 2022 – Apr 24, 2026
Health CarePharmaceuticals$120M
MVM
+$1.1M
TD Variance
1.333

Every news event mapped to its market reaction — 111 events, 50 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-03-09+90.9%newsBusiness WireAN2 Therapeutics Announces $40 Million Private Placement Financing
2026-03-09+90.9%newsSeeking AlphaAN2 Therapeutics raises $40M privately
2026-03-09+90.9%newsBenzingaAN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - Benzinga
2026-03-09+90.9%newsInvesting.comAN2 Therapeutics raises $40M in private placement - Investing.com
2026-03-09+90.9%newsYahoo FinanceAN2 Therapeutics Announces $40 Million Private Placement Financing - Yahoo Finance
2026-03-09+90.9%newsStocktwitsANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally? - Stocktwits
2024-02-12-79.1%newsSeeking AlphaBiggest stock movers today: Diamondback Energy, Joby Aviation, monday.com, and more
2024-02-12-79.1%newsSeeking AlphaAN2 Therapeutics plunges after pause on pivotal trial
2024-02-12-79.1%legalSEC EDGARANTX 8-K: 8.01 (SEC Filing)
2022-08-11+73.5%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.53 beats by $1.36
2022-08-11+73.5%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2024-08-08-61.1%legalSEC EDGARANTX 8-K: 2.05, 5.02, 7.01, 8.01 (SEC Filing)
2026-03-03+24.3%newsBusiness WireAN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
2024-02-13-23.8%newsSeeking AlphaAN2 Therapeutics extends losses as Leerink cuts on trial setback
2026-01-07+23.7%executiveInvesting.comAn2 therapeutics (ANTX): cfo Day sells $8883 in shares - Investing.com
2023-08-16+21.9%newsSeeking AlphaAN2 Therapeutics prices $70.0 million stock offering
2023-08-16+21.9%legalSEC EDGARANTX 8-K: 1.01, 8.01 (SEC Filing)
2023-08-17+21.3%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2024-03-28+17.0%newsSeeking AlphaAN2 Therapeutics reports FY results
2024-03-28+17.0%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2024-03-29+15.9%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17
2022-05-10+15.5%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$2.98 misses by $2.06
2022-05-10+15.5%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2026-01-09-14.5%analystYahoo FinanceAN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
2026-01-09-14.5%newsZacks Investment ResearchShould I buy AN2 Therapeutics (ANTX) - Zacks Investment Research
2026-01-09-14.5%newsYahoo FinanceAre Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance
2026-04-17+14.3%newsBenzinga12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
2026-04-22+12.0%newsStock TitanAN2 Therapeutics (ANTX) details 2026 meeting, board elections and pay - Stock Titan
2026-04-09-11.6%newsMT NewswiresAN2 Therapeutics Files $300 Million Mixed Shelf
2026-04-09-11.6%legalSEC EDGARANTX 8-K: 8.01 and (SEC Filing)
2026-04-09-11.6%expansionStock TitanAN2 Therapeutics (NASDAQ: ANTX) launches new $80M at-the-market stock sale - Stock Titan
2022-05-09-11.2%legalSEC EDGARANTX 8-K: 5.02 and (SEC Filing)
2026-04-21+10.1%legalStock Titan[EFFECT] AN2 Therapeutics, Inc. SEC Filing - Stock Titan
2022-11-19-9.4%analystZacks Investment ResearchWhat is the current Price Target and Forecast for AN2 Therapeutics (ANTX) - Zacks Investment Research
2023-09-13-9.2%legalSEC EDGARANTX 8-K: 8.01 and (SEC Filing)
2022-09-29+8.9%expansionSeeking AlphaAN2 Therapeutics secures $17.8M contract from NIH
2024-08-14-8.5%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.48
2023-08-23+8.0%newsSeeking AlphaAN2 Therapeutics up 5%, RA Capital buys $16M stock
2023-11-09-6.9%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2022-04-19-6.8%analystSeeking AlphaAN2 Therapeutics started at Oppenheimer at outperform on promise of antibiotic
2022-11-09-6.8%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.59 in-line
2022-11-09-6.8%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) director’s 44,466 stock options repriced to $3.91 - Stock Titan
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) director reprices fully vested options at $3.91 strike - Stock Titan
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) reprices stock options for company director - Stock Titan
2026-03-23-6.5%newsStock Titan[Form 4] AN2 Therapeutics, Inc. Insider Trading Activity - Stock Titan
2026-03-23-6.5%executiveStock TitanAN2 Therapeutics (ANTX) reprices Chief Development Officer stock options - Stock Titan
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) director logs repriced stock options and cancels older grants - Stock Titan
2026-03-23-6.5%executiveStock TitanCEO option repricing at AN2 Therapeutics (ANTX) detailed in Form 4 filing - Stock Titan
2026-03-23-6.5%newsStock TitanDirector at AN2 Therapeutics (ANTX) has stock options repriced - Stock Titan
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) reprices stock options for board director - Stock Titan
2026-03-23-6.5%executiveStock TitanAN2 Therapeutics (ANTX) CFO swaps higher-priced options for $3.91 grants - Stock Titan
2026-03-23-6.5%newsStock TitanAN2 Therapeutics (ANTX) officer sees large option repricing, no share sales - Stock Titan
2024-08-19+6.4%legalSEC EDGARANTX 8-K: 1.01, 3.03, 5.03 (SEC Filing)
2024-08-19+6.4%newsYahoo FinanceAN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why - Yahoo Finance
2026-04-20+6.1%newsStock TitanAN2 Therapeutics (NASDAQ: ANTX) files $80M at‑the‑market offering - Stock Titan
2026-03-21-5.3%newsThe Globe and MailAN2 Therapeutics Reprices Stock Options to Enhance Retention - The Globe and Mail
2024-05-14-5.1%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2023-10-04+5.1%newsSeeking AlphaAN2 Therapeutics director and 10% owner disposes stake in the company
2024-11-13-5.1%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2025-01-29-5.0%newsStock TitanAN2 Therapeutics Showcases Next-Gen Boron Chemistry Platform at Major Healthcare Summit - Stock Titan
2025-04-25-4.6%newsStock TitanANTX Stock Price, News & Analysis - Stock Titan
2026-01-29-4.5%legalSEC EDGARANTX 8-K: 5.02 (SEC Filing)
2025-11-12-4.2%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2023-11-10-4.1%earningsSeeking AlphaAN2 Therapeutics reports Q3 results
2026-03-31-4.0%newsBusiness WireAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
2026-03-31-4.0%newsStock Titan84-patient study tests oral drug for lung disease with no approved therapies - Stock Titan
2022-06-29-3.9%legalSEC EDGARANTX 8-K: 8.01 and (SEC Filing)
2025-05-14+3.6%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.35
2026-02-17-3.5%newsBusiness WireAN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
2025-11-10+3.5%newsStock TitanAN2 Therapeutics (NASDAQ: ANTX) partners with GSK on TB LeuRS; Gates funds third year - Stock Titan
2023-05-05+3.4%newsSeeking AlphaAN2 Therapeutics: Boron Chemistry For Infectious Diseases
2025-05-27-3.2%newsIntellectia AIANTX Forecast — Price Prediction for 2026. Should I Buy ANTX? - Intellectia AI
2025-06-20-3.2%legalSEC EDGARANTX 8-K: 3.02 and (SEC Filing)
2024-01-31+3.0%analysteToroAN2 Therapeutics Inc (ANTX) Stock Price, News & Analyst Forecast - eToro
2025-09-04-2.9%newssimplywall.stHere's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - simplywall.st
2023-08-10+2.8%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2026-03-10-2.8%legalSEC EDGARANTX 8-K: 1.01, 3.02, 7.01 (SEC Filing)
2026-03-10-2.8%newsTradingViewAN2 Therapeutics Raises $40 Million in Private Placement of Shares and Pre-Funded Warrants - TradingView
2026-03-10-2.8%newsTipRanksAN2 Therapeutics Announces $40 Million Private Placement Financing - TipRanks
2024-05-15-2.8%earningsSeeking AlphaAN2 Therapeutics reports Q1 results
2026-04-10-2.2%expansionThe Globe and MailAN2 Therapeutics Launches New $80 Million ATM Program - The Globe and Mail
2026-04-10-2.2%newsStock TitanAN2 Therapeutics (ANTX) director receives 1,192-share stock grant as fees - Stock Titan
2026-04-10-2.2%newsStock TitanAN2 Therapeutics (ANTX) director receives 3,775-share fully vested grant - Stock Titan
2026-04-10-2.2%newsStock TitanDirector at AN2 Therapeutics (NASDAQ: ANTX) awarded 3,775 shares - Stock Titan
2024-02-17+2.2%newsSeeking AlphaSpotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference
2024-11-05-1.9%legalSEC EDGARANTX 8-K: 5.02 (SEC Filing)
2024-04-28+1.8%newsTradingViewANTX Stock Price and Chart — NASDAQ:ANTX - TradingView
2025-11-13-1.7%earningsSeeking AlphaAN2 Therapeutics reports Q3 results
2025-03-25+1.6%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.25 beats by $0.01
2025-03-25+1.6%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2025-08-12-1.4%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.21 beats by $0.13
2026-03-20-1.4%legalSEC EDGARANTX 8-K: 5.02 (SEC Filing)
2026-03-20-1.4%newsStock TitanAN2 Therapeutics (ANTX) cuts exercise price on executive and employee options to $3.91 - Stock Titan
2026-03-11+1.3%newsSeeking AlphaAN2 Therapeutics, Inc. (ANTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
2026-03-11+1.3%executiveBenzingaAN2 Therapeutics Stock Cools Off After 90% Rally - Benzinga
2026-03-11+1.3%legalMinichartAN2 Therapeutics Secures $40 Million in Private Placement Financing to Advance Boron-Based Drug Pipeline - Minichart
2024-11-14+0.9%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.43
2023-05-11+0.7%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.79
2023-05-11+0.7%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2026-04-18+0.5%earningsUBND thành phố Hải PhòngAN2 Thera (ANTX) Stock Under Pressure (Investors Pile In) 2026-04-18 - Pre Earnings - UBND thành phố Hải Phòng
2026-03-17-0.4%newsBusiness WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
2026-03-17-0.4%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.29 misses by $0.05
2026-03-17-0.4%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2023-04-06+0.3%newsSeeking AlphaAN2 Therapeutics files for $300M mixed shelf offering
2023-03-29-0.3%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.61
2023-03-29-0.3%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2023-09-08-0.1%legalSEC EDGARANTX 8-K: 5.02 (SEC Filing)
2024-08-13-0.0%legalSEC EDGARANTX 8-K: 2.02 and (SEC Filing)
2024-08-13-0.0%earningsInvestorPlaceANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024 - InvestorPlace
2023-08-11-0.0%earningsSeeking AlphaAN2 Therapeutics GAAP EPS of -$0.81
tickerdossier.comtickerdossier.substack.com